Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 7/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745232 | 0.83 | STING1 (0.39) | FPR2STING1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5518077 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1ALPGPLAA | |
| SCHEMBL13724404 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1ALPGPLAA | |
| SCHEMBL2633151 | 0.72 | KMT2A (0.50) | FPR2SMN1; SMN2KDM4EALDH1A1ALPG | |
| SCHEMBL2627811 | 0.72 | SMN1; SMN2 (0.63) | FPR2SMN1; SMN2 | |
| SCHEMBL9498449 | 0.71 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1ALPGPLAA | |
| SCHEMBL3588076 | 0.71 | FPR2 (0.42) | FPR2HDAC6KDM4EALDH1A1 | |
| SCHEMBL6839749 | 0.71 | CTNNB1 (0.50) | STING1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1982420 | 0.71 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1ALPGPLAA | |
| SCHEMBL300078 | 0.70 | SMN1; SMN2 (0.47) | FPR2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| CN-115052596-B | ADAMTS inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-115052596-A | ADAMTS inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2021158626-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | FPR2 3705/4885STING1 3885/4885SMN1; SMN2 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.